Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

Fairmount is a Philadelphia-based investment firm dedicated to investing in promising new therapies pursued by biotechnology and life science companies.

Fairmount Funds

Sierra Oncology is a focused biopharma company that aims to impact global health by addressing high burden diseases through scientific research and innovation, particularly in infectious diseases, HIV, immunology/respiratory, and oncology.

Metric
Company Name	Clover Biopharmaceuticals, Ltd.	Fairmount Funds	Sierra Oncology
Symbol	2.20K
MSH ID	COM:CLOVERBIOPHARMA	COM:FAIRMOUNTFUNDS	COM:SIERRAONCOLOGY
Market	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare & Health Services
Industry	Biotechnology	Investment Management	Pharmaceuticals
Country	CN	US	GB
Stage	Post-IPO Equity
Employee Count	387
Website	cloverbiopharma.com	fairmountfunds.com	sierraoncology.com
LinkedIn	cloverbiopharmaceuticals	fairmount-funds-management-llc
Founders

Metric
Market Cap	53.38M
Enterprise Value
Monthly Web Traffic	3.49K	88
Web Traffic Growth	0.41	-0.70
Valuation
Raised Capital	36.90M

Metric
Revenue	5.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-230.14M
EBITDA	-354.93M
Operating Income	-358.92M
Net Income	-19.06M
EPS	-0.02
Diluted EPS	-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-15.46
Operating Profit Margin	-34.22
EBITDA Margin	-65.74
Net Profit Margin	-3.53
Return on Equity	2.08
Return on Assets	-0.07
Return on Capital Employed	14.86

BION

COM:BIONTECH

COM:BIONTECH

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.17
P/B Ratio	-0.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.95K
EV Multiple	-0.25

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	534.63
Operating Cycle	1.07K
Cash Conversion Cycle	1.03K
Asset Turnover	0.02

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt	-1.29
Operating Cash Flow/Sales	-10.96
Free Cash Flow Yield	-3.59

Metric
Cash & Equivalents	101.22M
Accounts Receivable
Inventory	95.87M
Goodwill
Debt to Capitalization	0.94
Debt to Assets	0.08
Current Ratio	1.55
Quick Ratio	0.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue